In patients with ARDS enrolled in the FACT Trial who received a PAC, we demonstrated that higher plasma GDF-15 levels are associated with an increased mortality and fewer ventilator-free, ICU-free, and organ failure-free days. This evidence concerns the gene GDF15 and acute respiratory distress syndrome.